Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

Annals of Oncology

Volumn 15, Issue 10, 2004, Pages 1510-1516

  deGraffenried, L A ^a   Fulcher, L ^a   Friedrichs, W E ^a   Grunwald V ^b   Ray, R B ^c   Hidalgo, Manuel ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Breast cancer; PI3K Akt; PTEN

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHROMONES; ENZYME INHIBITORS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MORPHOLINES; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 6944238452     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh388     Document Type: Article

References (26)

1. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-67.
2. Marsh DJ, Dahia PL, Zheng Z et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16: 333-334.
3. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264: 29-41.
4. Garcia JM, Silva JM, Dominguez G et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999; 57: 237-243.
5. Campbell RA, Bhat-Nakshatri P, Patel NM et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-9824.
6. Lu Y, Lin YZ, LaPushin R et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999; 18: 7034-7045.
7. Tanaka M, Koul D, Davies MA et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000; 19: 5406-5412.
8. Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001; 61: 5275-5283.
9. Page C, Lin HJ, Jin Y et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000; 20: 407-416.
10. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997.
11. Sekulic A, Hudson CC, Homme JL et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000; 60: 3504-3513.
12. Gingras AC, Kennedy SG, O'Leary MA et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998; 12: 502-513.
13. Podsypanina K, Lee RT, Politis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98: 10320-10325.
14. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319.
15. Huang S, Liu LN, Hosoi H et al. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61: 3373-3381.
16. Hosoi H, Dilling MB, Shikata T et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886-894.
17. Grewe M, Gansauge F, Schmid RM et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59: 3581-3587.
18. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6686.
19. Ghosh AK, Grigorieva I, Steele R et al. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. Gene 1999; 235: 85-91.
20. Durgam VR, Fernandes G. The growth inhibitory effect of conjugated linoleic acid on MCF-7 cells is related to estrogen response system. Cancer Lett 1997; 116: 121-130.
21. Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
22. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000; 90: 39-44.
23. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
24. Gera JF, Mellinghoff IK, Shi Y. AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2003; 279: 2737-2746.
25. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001; 98: 136-141.
26. deGraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004; in press.